SCHEMBL342792

SCHEMBL342792

Cc1cc(Nc2ccn[nH]2)nc(N2C[C@H](C(=O)O)C[C@H](c3ccccc3)C2)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.41
EGFR P00533 2/20 0.39
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
ROCK2 O75116 3/20 0.39
HCRTR1 O43613 3/20 0.38
HCRTR2 O43614 3/20 0.38
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ROCK1 Q13464 1/20 0.36
POLB P06746 1/20 0.35
MAT2A P31153 1/20 0.35
RBP4 P02753 1/20 0.35
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342794 1.00 RET (0.41) RETEGFRKDM4EHSD17B10MEN1
SCHEMBL342793 1.00 RET (0.41) RETEGFRKDM4EHSD17B10MEN1
Trifluoroacetic Acid SCHEMBL474405 0.95 AURKA (0.40) RETEGFRKDM4EHSD17B10MEN1
Trifluoroacetic Acid SCHEMBL342171 0.95 AURKA (0.40) RETEGFRKDM4EHSD17B10MEN1
Trifluoroacetic Acid SCHEMBL342173 0.95 AURKA (0.40) RETEGFRKDM4EHSD17B10MEN1
SCHEMBL343434 0.93 RET (0.40) RETEGFRKDM4EALDH1A1ROCK2
SCHEMBL343433 0.93 RET (0.40) RETEGFRKDM4EALDH1A1ROCK2
SCHEMBL343435 0.93 RET (0.40) RETEGFRKDM4EALDH1A1ROCK2
SCHEMBL342160 0.89 IDH2 (0.41) RETKDM4EHSD17B10MEN1ALDH1A1
SCHEMBL342158 0.89 IDH2 (0.41) RETKDM4EHSD17B10MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367690-B2 Aminopyridine derivatives having aurora a selective inhibitory action VERTEX PHARMACEUTICALS INC. (US) 2013-02-05 US claimed
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICALS CO., LTD. (JP) 2012-01-19 US claimed
US-8367690-B2 Aminopyridine derivatives having aurora a selective inhibitory action VERTEX PHARMACEUTICALS INC. (US) 2013-02-05 US disclosed
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICALS CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015969-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION AURKA, AURKC, AURKB RET 1430/4885EGFR 987/4885KDM4E 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.